ROIVANT SCIENCES LTD. Finance Lease, Right-of-Use Asset, Amortization
ROIVANT SCIENCES LTD. (ROIV) reported Finance Lease, Right-of-Use Asset, Amortization of $454.00 thousand for the 12-month period ending 2023-03-31, per its 10-K filed 2023-06-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2023-06-28
- ROIVANT SCIENCES LTD. finance lease, right-of-use asset, amortization for fiscal 2023 was $454.00K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|
| 2023-03-31 | $454.00K 10-K · filed 2023-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |